Nalbuphine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 535708

CAS#: 20594-83-6

Description: Nalbuphine is a narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Discontinued.


Chemical Structure

img
Nalbuphine
CAS# 20594-83-6

Theoretical Analysis

MedKoo Cat#: 535708
Name: Nalbuphine
CAS#: 20594-83-6
Chemical Formula: C21H27NO4
Exact Mass: 357.19
Molecular Weight: 357.450
Elemental Analysis: C, 70.56; H, 7.61; N, 3.92; O, 17.90

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Nalbuphine

IUPAC/Chemical Name: Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5alpha,6alpha)-

InChi Key: NETZHAKZCGBWSS-RLVOKJKJSA-N

InChi Code: InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16-,19+,20+,21-/m1/s1

SMILES Code: OC1=CC=C2C[C@@H](N(CC3CCC3)CC4)[C@]5(O)CC[C@@H](O)[C@@]6([H])[C@]54C2=C1O6

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 357.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain. 2016 Jan;32(1):87-93. doi: 10.1097/AJP.0000000000000211. PMID: 26650717.


2: Davis MP, Fernandez C, Regel S, McPherson ML. Does nalbuphine have a niche in managing pain? J Opioid Manag. 2018 Mar/Apr;14(2):143-151. doi: 10.5055/jom.2018.0441. PMID: 29733100.


3: Reiter PD, Clevenger AC. Nalbuphine Reduces Opioid-Associated Urinary Retention in Pediatric Patients. Pediatr Crit Care Med. 2019 May;20(5):e240-e244. doi: 10.1097/PCC.0000000000001920. PMID: 31013261.


4: Deng C, Wang X, Zhu Q, Kang Y, Yang J, Wang H. Comparison of nalbuphine and sufentanil for colonoscopy: A randomized controlled trial. PLoS One. 2017 Dec 12;12(12):e0188901. doi: 10.1371/journal.pone.0188901. PMID: 29232379; PMCID: PMC5726642.


5: Kubica-Cielińska A, Zielińska M. The use of nalbuphine in paediatric anaesthesia. Anaesthesiol Intensive Ther. 2015;47(3):252-6. doi: 10.5603/AIT.2015.0036. PMID: 26165241.


6: Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG. Nalbuphine. Drug Alcohol Depend. 1985 Feb;14(3-4):339-62. doi: 10.1016/0376-8716(85)90066-3. PMID: 2986929.


7: Liang RJ, Shih YN, Chen YL, Liu WY, Yang WL, Lee SY, Wang HJ. A dual system platform for drug metabolism: Nalbuphine as a model compound. Eur J Pharm Sci. 2020 Jan 1;141:105093. doi: 10.1016/j.ejps.2019.105093. Epub 2019 Oct 21. PMID: 31648049.


8: Inan S, Torres-Huerta A, Jensen LE, Dun NJ, Cowan A. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol. 2019 Dec 1;864:172702. doi: 10.1016/j.ejphar.2019.172702. Epub 2019 Sep 27. PMID: 31568781; PMCID: PMC6913640.


9: Narver HL. Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice. Lab Anim (NY). 2015 Mar;44(3):106-10. doi: 10.1038/laban.701. PMID: 25693108.


10: Schultz-Machata AM, Becke K, Weiss M. Nalbuphin in der Kinderanästhesie [Nalbuphine in pediatric anesthesia]. Anaesthesist. 2014 Feb;63(2):135-43. German. doi: 10.1007/s00101-014-2293-z. PMID: 24504192.